June 10, 2009

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A.   Lancet.   2009 May 30;373(9678):1849-60

Nephrologists often see patients at elevated vascular risk and may consider using aspirin for primary or secondary prophylaxis. This meta-analysis confirms the known benefit of aspirin for secondary prophylaxis, but raises some questions as to the balance of risks and benefits for primary prophylaxis in the general population.

Related Articles:

Internal Medicine for Nephrologists
  • Generic Viagra

    I think with this type of informed consent, renal patients would pick primary prophylaxis with ASA.
    Kamagra

  • Guest

    In the renal patients, given the significantly elevated risk of vascular events, likely important to counsel our patients about potential sequelae of vascular events vs GI bleed. I suspect with this type of informed consent, most renal patients would choose primary prophylaxis with ASA.